| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.0042 | 0.9 |
| mRNA | BRD-K41334119 | CTRPv2 | pan-cancer | AAC | 0.007 | 0.9 |
| mRNA | BRD-K90370028 | CTRPv2 | pan-cancer | AAC | -0.0049 | 0.9 |
| mRNA | BRD-K86535717 | CTRPv2 | pan-cancer | AAC | -0.0062 | 0.9 |
| mRNA | PD-0332991 | FIMM | pan-cancer | AAC | 0.012 | 0.9 |
| mRNA | I-BET151 | CTRPv2 | pan-cancer | AAC | 0.002 | 0.9 |
| mRNA | temsirolimus | FIMM | pan-cancer | AAC | -0.0099 | 1 |
| mRNA | BI-2536 | FIMM | pan-cancer | AAC | -0.0055 | 1 |
| mRNA | BMS-270394 | CTRPv2 | pan-cancer | AAC | -0.0015 | 1 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.0023 | 1 |